NCT01067820 - ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation | Biotech Hunter

Enrollment

324

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

June 30, 2013

Conditions

Coronary Artery Disease

Interventions

DRUG

RVX000222

capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks

DRUG

Placebo RVX000222

capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks

Trial Locations (58)

1091

Amsterdam

1200

Brussels

1814

Alkmaar

1900

La Plata

3079

Rotterdam

3400

Corrientes

3600

Genk

5000

Córdoba

5623

Eindhoven

6000

Charleroi

6532

Nijmegen

7513

Enschede

8011

Zwolle

15706

Santiago de Compostela

28040

Madrid

28046

Madrid

29010

Málaga

30203

Cartagena

33203

Gijón

36214

Vigo

39008

Santander

48960

Galdakao

101990

Moscow

117931

Moscow

121552

Moscow

143420

Moscow

191104

Saint Petersburg

197341

Saint Petersburg

460000

Orenburg

634012

Tomsk

C1180AAX

Buenos Aires

C1428DCO

Buenos Aires

X5000EPU

Córdoba

X5003DCE

Córdoba

X5006IKK

Córdoba

X5016KEH

Córdoba

B1642DJN

San Isidro

B-2650

Edegem

70390-700

Brasília

29156-580

Cariacica

80320-320

Curitiba

74223-130

Goiânia

90020-090

Porto Alegre

04012-909

São Paulo

05403-000

São Paulo

38400-368

Uberlândia

H-1023

Budapest

H-1106

Budapest

H-1122

Budapest

H-1134

Budapest

H-7624

Pécs

H-6720

Szeged

40-635

Katowice

02-507

Warsaw

04-628

Warsaw

08916

Badalona

08035

Barcelona

08907

Barcelona

All Listed Sponsors

collaborator

The Cleveland Clinic

OTHER

lead

Resverlogix Corp

INDUSTRY